Previous studies demonstrated that low dose LPS injection(s) lead to increased Aβ deposition in APP/PS1 mice [40, 64] while other studies failed to show this LPS effect in first-generation AD mouse models [31]. This evidence concerns the gene PSEN1 and Alzheimer disease.